- Home
- AEE vs ILMN Comparison
AEE vs ILMN Comparison
Compare AEE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- ILMN
- Stock Information
- Founded
- AEE 1901
- ILMN 1998
- Country
- AEE United States
- ILMN United States
- Employees
- AEE N/A
- ILMN N/A
- Industry
- AEE Power Generation
- ILMN Medical Specialities
- Sector
- AEE Utilities
- ILMN Health Care
- Exchange
- AEE Nasdaq
- ILMN Nasdaq
- Market Cap
- AEE 27.3B
- ILMN 16.0B
- IPO Year
- AEE N/A
- ILMN 2000
- Fundamental
- Price
- AEE $98.66
- ILMN $103.03
- Analyst Decision
- AEE Buy
- ILMN Buy
- Analyst Count
- AEE 10
- ILMN 15
- Target Price
- AEE $104.20
- ILMN $123.67
- AVG Volume (30 Days)
- AEE 1.3M
- ILMN 1.3M
- Earning Date
- AEE 11-05-2025
- ILMN 11-03-2025
- Dividend Yield
- AEE 2.88%
- ILMN N/A
- EPS Growth
- AEE 2.91
- ILMN N/A
- EPS
- AEE 4.55
- ILMN 7.91
- Revenue
- AEE $8,119,000,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- AEE $15.13
- ILMN N/A
- Revenue Next Year
- AEE $6.13
- ILMN $2.76
- P/E Ratio
- AEE $21.70
- ILMN $13.06
- Revenue Growth
- AEE 17.75
- ILMN N/A
- 52 Week Low
- AEE $82.95
- ILMN $68.70
- 52 Week High
- AEE $104.10
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- AEE 41.87
- ILMN 57.64
- Support Level
- AEE $98.51
- ILMN $95.12
- Resistance Level
- AEE $101.17
- ILMN $104.22
- Average True Range (ATR)
- AEE 1.11
- ILMN 3.33
- MACD
- AEE -0.22
- ILMN 0.47
- Stochastic Oscillator
- AEE 22.53
- ILMN 88.42
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.